Company ProfilePremium

AbClon Inc.

Company Profile Analysis

Ticker: 174900.KQ앱클론 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
AbClon Inc. - Company showcase

Year Founded & Workforce

2010

67 Employees

AbClon Inc. logo

AbClon Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AbClon Inc. Overview

AbClon is a Seoul-based, clinical-stage oncology biotech. It was founded in 2010 by Lee Jong-seo and Swedish collaborators from the Human Protein Atlas programme. Its edge is epitope discovery: the NEST platform finds antibodies that bind new sites on validated cancer targets.

That approach has produced two clinical assets. The first is AC101 (HLX22), a HER2 antibody licensed worldwide to Shanghai Henlius. It is in a global Phase 3 trial (about 550 patients) for first-line HER2-positive gastric cancer, with launch targeted for 2028. The second is nespecel (AT101), a CD19 CAR-T built on a proprietary humanised binder (h1218) rather than the FMC63 binder used by all approved CD19 CAR-Ts. Its Korean Phase 2 completed enrolment in July 2026, and a Korean approval filing is planned by end-2026. Chong Kun Dang holds Korean marketing priority rights.

Behind these sit a switchable CAR-T platform (zCAR-T), 4-1BB bispecifics (AffiMab), and a new in vivo CAR-T effort with Strike Pharma and GC Biopharma. Revenue is small: KRW 4.7bn in FY2025. Operating losses run at about KRW 15–18bn a year, funded by repeated equity-linked raises.


Company self-description (paraphrased from IR and disclosure materials)

AbClon describes itself as an innovative antibody-drug venture focused on hard-to-treat cancers. It operates three core discovery platforms, NEST, AffiMab and CAR-T, and maintains a repeatable process for generating new antibody drug candidates.

Its business model, as described to data vendors and in its disclosures, combines several elements:

  • Collaborative research with Swedish partners, including Atlas Therapeutics, Affibody and Alligator Bioscience.

  • Licensing of candidates at the preclinical or early clinical stage to monetise discovery output.

  • A newer ambition to commercialise its own CAR-T in Korea through Chong Kun Dang (Valueline company summary, 2Q26 update; AbClon IR deck, Mar-2026).

The March 2026 IR deck frames the company as a global bio-innovator. It says AbClon develops next-generation CAR-T and bispecific immunotherapies on top of a differentiated antibody platform.

Independent characterisation

What the company does. AbClon is an R&D-stage platform biotech with two de-risked assets and a long preclinical tail.

  • The antibody franchise has already been out-licensed. AC101/HLX22 is Henlius' asset to develop and sell. AbClon's economic interest is limited to:

    • Remaining milestones. All USD 30M of global-deal milestones are sales-based.

    • Tiered royalties of 3–5% on product sales.

    • Alligator Bioscience is entitled to 35% of AbClon's Henlius-derived income. AbClon therefore keeps roughly 65% of that income.

    • (NewDaily, 2 Sep 2026; Alligator Bioscience press release, 23 Apr 2026)

  • The cell-therapy franchise is owned and operated by AbClon:

    • It runs clinical development of nespecel itself.

    • It owns a small GMP facility.

    • It has licensed Turkish rights to TCT Health Technology and given Chong Kun Dang a domestic sales-priority right.

Revenue model today. Reported revenue is not drug revenue. It comes mainly from product sales of reagents and analytical standards, many won through public tenders from Korean agencies such as the Korea Disease Control and Prevention Agency (KDCA) and the National Institute of Food and Drug Safety Evaluation (NIFDS). Smaller amounts come from service income and occasional licence milestones.

  • 2Q26 revenue mix: 85% goods, 15% services (Butler.works, based on the 2Q26 filing).

  • Contract examples:

    • KDCA reagent contract: KRW 309M (27 Aug 2025).

    • NIFDS pesticide-residue reference-standard contract: KRW 778M (9 Mar 2026).

    • NIFDS supply contract: KRW 824M (4 Aug 2026).

    • (DART filings as reported by DigitalToday, Dealsite and AlphaDistill)

  • The FY2024 revenue miss (KRW 2.34bn) happened because auditors required goods sales to be booked net rather than gross (Dealsite, 15 May 2025). This shows how thin and accounting-sensitive the base is.

Value chain position. AbClon sits in upstream discovery and early-to-mid clinical development. For nespecel it has moved into late-stage development and small-scale manufacturing. It has no sales force. Commercialisation is delegated to partners: Henlius globally for AC101, Chong Kun Dang in Korea and TCT in Türkiye for nespecel.

Customer types.

  • Licensees and pharma partners: Henlius, TCT, Chong Kun Dang.

  • Government laboratories buying reagents.

  • Prospectively, hospitals and payers for CAR-T in Korea, via its partner.

End-markets.

  • HER2-positive gastric and gastro-oesophageal junction cancer (first line).

  • HER2-positive and HER2-low breast cancer, through Henlius.

  • Relapsed/refractory large B-cell lymphoma (third line, possibly second line later).

  • Preclinical solid tumours: prostate, colorectal, ovarian and other HER2-expressing tumours.

  • Autoimmune disease (preclinical).

  • Neurological disease (BBB-shuttle discovery).

Revenue model mix (FY2025, qualitative).

  • Product (reagent/standard) sales: majority.

  • Services: minority.

  • Licensing: episodic.

  • Subscription: none.

  • No royalty income has been booked yet, because no AbClon-originated drug is marketed.

Strategy

Stated strategy (paraphrased from IR, Mar-2026, and management statements)

Theme 1 — Differentiated epitopes: Use the NEST platform to find binding sites on validated targets that deliver new mechanisms, such as dual HER2 blockade with trastuzumab or a CD19 epitope that FMC63 cannot reach.

Theme 2 — From licensor to commercial-stage company: Secure Korean approval of nespecel, giving AbClon a first owned commercial product. Use partner channels: Chong Kun Dang in Korea and TCT for Türkiye, Europe and the Middle East.

Theme 3 — Early licensing as a funding model: Out-license preclinical and early clinical assets such as AM109, AT501 and in vivo CAR-T to generate cash, as already done with AC101.

Theme 4 — Next-generation cell therapy: In vivo CAR-T is positioned as the next growth engine: same-day "off-the-shelf" dosing without leukapheresis or lymphodepletion (BioSpectator, 30-Jan-2026). zCAR-T is positioned for solid tumours.

Management framing: The company called 2026 the year it would shed administrative-issue status and leap to a global biotech (shareholder letter reported by Kukinews, 30-Jan-2026).

Initiatives announced in the last 24 months

DateInitiativeDetailSource
Feb-2025TCT Türkiye licenceCovers the CAR sequence plus manufacturing, analytics and CMC transfer. TCT bears all Turkish development and commercial costs; milestones are tied to IND; royalties on net sales.BioSpectator
May-2025Chong Kun Dang allianceEquity investment plus Korean sales priority for nespecel. A joint development committee covers HER2 CAR-T (AT501) and PSMA, CD30 and 4-1BB programmes.CEO Score Daily
Jul/Sep-2025MFDS expedited pathwayApplied 23-Jul-2025; designated 24-Sep-2025Korea Economic Daily
Oct-2025Capital structure resetKRW 36bn of equity-classified perpetual CB and CPS to cure the pre-tax-loss testDealsite
Jan-2026In vivo CAR-T platform launchBuilt through Swedish biotech and domestic partnershipsBioSpectator
Feb-2026Strike Pharma Eurostars projectStAb19 (in vivo CD19), up to EUR 1MCB Insights / BioSpectator
Apr-2026AACR 2026 out-licensing pushzCAR-T and AM109 dataKorea Economic Daily
Jun-2026GC Biopharma in vivo CAR-T partnershipJoint platform, then preclinical, clinical and global partneringBioSpectator
Jul-2026TCT co-development cooperation (expanded)Headline reported; terms not disclosedAsia Economy headline list
2026 (planned)Investigator-initiated trial in post-CAR-T relapse; second-line investigator trial; Türkiye IND; AT501 INDPer IR timelineAbClon IR

Medium-term targets and guidance

ItemTargetSource
Nespecel MFDS approval filingBy end-2026Dealsite, Jul-2026
Nespecel Korean launch2,027Dealsite, Jul-2026
HLX22 Phase 3 topline1H27 (AbClon) vs 2H27 (Henlius, Aug-2026)NewDaily
HLX22 commercial launch2028 (both companies)NewDaily
AT501 IND2,026IR
HLX49 IND2026 (Henlius)Asia Economy

Financial guidance: no revenue or profit guidance has been issued.

ESG and sustainability commitments: none disclosed.

Products & Services

AbClon has no marketed drugs. The catalogue below covers every disclosed pipeline programme, grouped by platform (AbClon IR deck, Mar-2026, pages 5–6, unless noted).

NEST platform (Novel Epitope Screening Technology) — monoclonal antibodies

AC101 (Henlius code HLX22) — anti-HER2 monoclonal antibody

Mechanism: - Binds subdomain IV of HER2 at a different site from trastuzumab, so the two antibodies can bind HER2 at the same time.

  • Together they promote HER2 internalisation and degradation of HER2 dimers.

  • Published work (J Transl Med, Jul-2024; Med, Jul-2024) reports inhibition of both HER2/HER2 homodimers and HER2/EGFR heterodimers, with HER2 internalisation increased by roughly 40–80% (AbClon IR).

Licensee: - Shanghai Henlius Biotech, a Fosun Pharma company. It holds worldwide rights: China since 2016, global since 2018.

Clinical programmes (Henlius-run): 1. First-line HER2+ gastric/GEJ cancer, Phase 3 (PHAROS001 / HLX22-GC-301; NCT06532006).

  • Regimen: AC101 at 15 mg/kg plus trastuzumab plus chemotherapy (± pembrolizumab), versus placebo plus trastuzumab plus chemotherapy (± pembrolizumab).

  • Design: about 550 patients; dual primary endpoints of PFS and OS.

  • Enrolment: 428 patients (77.8%) by Aug-2026. Regional split: China 58.4%, Japan 12.1%, Europe 11.9%, US 4.7%, other 12.9%.

  • Topline: Henlius now guides to 2H27; AbClon's 13-Aug-2026 shareholder letter still said 1H27.

  • Launch target: 2028.

  • Sources: NewDaily (2 Sep 2026); BioSpectator.

  1. HER2-low, HR+ breast cancer, Phase 2 (China). AC101 plus trastuzumab deruxtecan (Enhertu). First patient Apr-2025; enrolment completed Feb-2026 (AbClon IR).

  2. First-line HER2+ breast cancer, Phase 2/3. AC101 plus HLX87 (Henlius' HER2 ADC), with the aim of a chemotherapy-free regimen. First patient Feb-2026 (AbClon IR).

  3. Neoadjuvant HER2+ breast cancer. AC101 plus HLX87, investigator-initiated trial (AbClon IR).

  4. HER2-expressing solid tumours, Phase 2 (China). AC101 plus trastuzumab plus chemotherapy, or AC101 plus Enhertu. NMPA approval reported Dec-2024 (BioSpectator).

  5. Other indications listed in the IR deck: HER2 pancreatic cancer, and HER2 gastric cancer with serplulimab (anti-PD-1). AbClon states that AC101 is in clinical trials across six indications (Asia Economy, Apr-2026).

Regulatory status: - US FDA Orphan Drug Designation for gastric cancer (Mar-2025).

  • European Commission Orphan Drug Designation (May-2025).

  • Source: BioSpectator.

Key efficacy data (HLX22 Phase 2, first-line HER2+ gastric cancer)

  • Median PFS not reached at 39 months of follow-up; PFS hazard ratio 0.20.

  • OS hazard ratio 0.60 (95% CI 0.28–1.21; not yet statistically mature).

  • Two-year PFS 54.8% versus 17.5% for control.

  • Control median PFS 8.2–8.3 months.

  • Sources: NewDaily (Sep-2026); AbClon IR; ESMO GI 2024 via BioSpectator.

Pricing: - Not applicable to AbClon (licensed). Royalties of 3–5% are tiered by sales band.

HLX49 — HER2 biparatopic ADC (Henlius-originated derivative)

  • Combines the AC101 binding site (domain IV) with the trastuzumab binding site (domain II) in a single ADC.

  • Preclinical data at AACR 2026:

    • Higher internalisation and anti-tumour activity than Enhertu in BT-474 and NCI-N87 models.

    • Tumour reduction after a single 6 mg/kg dose.

    • Activity in HER2-ultralow (IHC <1+) models.

    • No serious toxicity in primates up to 60 mg/kg repeat dosing.

  • Henlius targets an IND in 2026.

  • Alligator holds participation rights in HLX49 and future derivatives, which implies AbClon's agreement covers derivatives.

  • Sources: Asia Economy (22 Apr 2026); Alligator Bioscience (23 Apr 2026).

AC104 — anti-VEGFR2 antibody

  • European patent granted May-2020.

  • Current development status not disclosed (Dealsite/PaxNet, 2020).

CAR-T platform — autologous (ex vivo)

AT101 / nespecel (nespe-cel, 네스페셀) — CD19 CAR-T

Construct and mechanism: - Humanised anti-CD19 scFv "h1218", discovered with NEST, plus a 4-1BB co-stimulatory domain and a CD8 hinge (IR schematic).

  • h1218 binds a membrane-proximal epitope (exon 2) of CD19. FMC63, used in Kymriah, Yescarta, Breyanzi, Tecartus and (as a modified version) Autolus' product, binds exons 3–4 further from the membrane.

  • The binder has fast on/off kinetics, which the company calls "Flying Kiss". It argues this limits T-cell exhaustion and enables serial killing (Molecular Cancer, Dec-2023).

  • Claimed benefits:

    • Activity against CD19 variants and masked CD19 that escape FMC63-based products.

    • Lower immunogenicity because the binder is humanised.

    • Freedom to operate outside FMC63 intellectual property.

Clinical programmes: 1. Third-line r/r DLBCL — Phase 1/2 (NCT05338931), registrational intent for Korea.

  • Phase 1 (n=12, four hospitals): MTD not reached; CR 66.7%, ORR 91.7%. Mid- and high-dose cohorts are reported variously as CR 83% / ORR 100% (initial CRO readout) or 6/6 CR (later update).

  • Phase 1 follow-up: 16.4-month OS rate 82.5% and PFS rate 66.7% (ASCO 2024).

  • Phase 2 (seven hospitals; 5×10^6 cells/kg; fludarabine/cyclophosphamide conditioning):

    • EHA 2025 interim: 45 enrolled, 44 manufactured (97.8%), 35 dosed, 32 evaluable.

    • ORR 94%; CR 63%, later updated to 68%.

    • Enrolment completed 2-Jul-2026. Final data and an MFDS filing are planned within 2026, with launch targeted for 2027.

  • Sources: BioSpectator; Finance Scope; Dealsite (Jul-2026).

  1. r/r DLBCL after prior CAR-T failure. Asan Medical Center investigator-initiated trial; IND planned for 2026 (Dailypharm, Dec-2025; AbClon IR).

  2. Türkiye, second/third-line DLBCL. Partnered with TCT; IND planned for 2026 (AbClon IR).

  3. Second-line DLBCL expansion. Investigator-initiated trial; IND planned for 2026 (AbClon IR).

Regulatory designations (MFDS): - Orphan drug (development stage).

  • Advanced biopharmaceutical expedited-review designation (Sep-2025).

  • GIFT (Global Innovative products on Fast Track).

Patents: - Korea, US, Japan, China, Canada and Australia granted; exclusivity runs to at least 2038.

  • Europe (EP3722313) under examination.

Pricing: - Not yet set. The CEO has spoken of up to about KRW 700bn in annual sales potential as a long-run aspiration (Korea Economic Daily, Dec-2025).

AT201 — CD19 dual/tandem CAR-T (blood cancer). Discovery/preclinical.

AT301 — PSMA CAR-T (prostate cancer). Discovery/preclinical.

AT601 — CD30 CAR-T with BTLA knockout (CD30+ lymphoma). Preclinical. Co-developed with UPenn; US patent granted Jul-2026 (THE VC news feed; Asia Economy).

Allogeneic CAR-T programme. Enabled by the 2022 G+FLAS CRISPR licence. Current status not disclosed.

zCAR-T switchable CAR-T platform

Concept: - A universal CAR recognises cotinine, a nicotine metabolite with an LD50 of 2–4 g/kg.

  • A separate "switch" molecule (cotinine conjugated to an affibody about 1/25 the size of an antibody) links the CAR-T cell to a tumour antigen.

  • Changing the switch dose and schedule turns T-cell activity up or down, which addresses cytokine release syndrome. Swapping the affibody re-targets the same cells to a different antigen.

Programmes: AT501 (HER2; gastric, breast and ovarian solid tumours): Preclinical. Switch-dependent tumour clearance shown in vivo. An IND is targeted in 2026 (IR, Mar-2026). US platform patent granted Sep-2025 (Kormedi).

AT502 (PD-L1; solid tumours): Preclinical.

AffiMab bispecific platform (antibody plus affibody)

AM105 (EGFR × 4-1BB, CD137) — metastatic colorectal cancer: - Activates T cells only when bound to EGFR on tumour cells, so activity does not depend on downstream EGFR mutations.

  • Targets cetuximab-resistant patients and "cold" tumours.

  • Preclinical.

  • AM109 (PSMA × 4-1BB) — metastatic castration-resistant prostate cancer.

    • AACR 2026 data in animal models: complete responses at very low doses (0.1–0.3 mg/kg).

    • Preclinical; out-licensing targeted.

    • Sources: BioSpectator (Mar-2026); AlphaDistill.

  • AM201 (TNFα × IL-6) — autoimmune disease, including rheumatoid arthritis. Preclinical.

In vivo CAR-T

InCAR-T / StAb19 (CD19): - Uses the same CD19 binder sequence as nespecel, delivered as mRNA in a T-cell-targeted (CD3-directed "pTag") LNP from Strike Pharma (Sweden).

  • Selected for a Eurostars grant of up to EUR 1M in Feb-2026.

  • A parallel programme with GC Biopharma combines GC's mRNA-LNP platform and GMP capacity with AbClon's CAR and antibody know-how (Jun-2026).

  • Stage: discovery.

  • Sources: CB Insights/BioSpectator (Feb-2026); BioSpectator (Jun-2026).

NeuroTaG BBB shuttle

  • Shuttle antibodies against TfR1, IGF1R and CD98 for delivering drugs to the brain.

  • Discovery stage (IR, Mar-2026).

Non-pharmaceutical products and services

  • Research and diagnostic reagents, antibody detection reagents, and analytical reference standards such as pesticide-residue standards.

  • Sold mainly through public tenders to KDCA and MFDS/NIFDS.

  • Supplied via outsourced production (DART supply-contract filings).

  • AlphaDistill estimates about KRW 0.25bn of stable quarterly goods revenue.

Financial Narrative

Basis. K-IFRS standalone statements (AbClon has no subsidiaries). FY2021–FY2024 income-statement figures are rounded DART-derived values from Butler.works. FY2025 and balance-sheet data come from Valueline's DART-derived statements. All figures are in KRW bn.

Income statement

Revenue CAGR FY2021–FY2025: about 11.9% a year (from KRW 3.0bn to KRW 4.71bn; computed).

Notes

  • FY2025 detail is from Valueline (DART-derived).

  • The FY2025 EPS of KRW -933 is Valueline's figure.

  • No dividend has ever been paid. The company has an accumulated deficit of KRW 90.8bn at end-2025 (Valueline balance sheet), which legally rules out dividends.

Commentary.

Revenue: The top line is immaterial to valuation and lumpy. It follows the timing of government tenders more than any operating trend.

  • FY2024 fell to KRW 2.34bn because goods sales had to be booked on a net basis.

  • FY2025 doubled to KRW 4.71bn, about 87% of it booked in 1Q–3Q.

  • 1Q26 was only KRW 0.43bn, far below the KRW 1.3–1.5bn that independent research had expected (AlphaDistill).

Losses: Operating losses widened every year from FY2022 (KRW -8.7bn) to FY2025 (KRW -17.6bn). The drivers were Phase 2 CAR-T clinical costs and manufacturing.

  • 1Q26 showed a sharp cut: the operating loss fell 47% year on year, entirely because SG&A dropped from KRW 5.87bn to KRW 3.31bn.

  • 2Q26 then saw losses jump back to KRW 6.2bn as Phase 2 dosing completed. The 1H26 operating loss (KRW 9.3bn) is essentially flat against 1H25 (KRW 9.1bn).

Gross margin: The FY2025 gross margin (24%) is low because personnel and depreciation are allocated into cost of sales.

Balance sheet

FY2021 balance-sheet data were not available in the sources reviewed.

Notes

  • Source: Valueline (DART-derived standalone).

  • Short-term debt consists of KRW 7.0bn of bank borrowings in every year plus short-term bonds/CB: KRW 5.52bn (FY2023) and KRW 10.10bn (FY2024).

  • Net debt is computed as total debt minus cash minus short-term financial instruments.

  • Shares outstanding come from Valueline's share-count series.

Commentary.

Funding pattern: Equity has been restored repeatedly through external capital. Equity more than doubled from KRW 29.4bn to KRW 60.4bn in FY2025 despite a KRW 17.9bn loss, because the company raised:

  • KRW 12.2bn from Chong Kun Dang (common equity).

  • KRW 25.2bn of perpetual CB, classified as equity.

  • KRW 10.8bn of CPS.

  • Gross external investment in 2025 was KRW 48.4bn (Korea Economic Daily, Dec-2025).

Pre-tax loss test: The KOSDAQ rule on pre-tax losses exceeding 50% of equity (법차손) had reached 55.4% at end-2024 (Dealsite). The 2025 equity raises were explicitly designed to cure it.

Property reclassification: In FY2025 about KRW 15bn of land moved from property, plant and equipment to investment property. PP&E land fell from KRW 19.08bn to KRW 4.07bn, and investment property of KRW 15.0bn appeared.

Cash flow

Notes

  • Source: Valueline trailing-twelve-month cash-flow series; the Dec-2025 column equals FY2025. FCF is computed as operating cash flow minus capex.

  • FY2025 financing breakdown:

    • Inflows of KRW 48.11bn: bonds KRW 25.15bn, CPS KRW 10.78bn, other equity KRW 12.17bn.

    • Repayment of KRW 10.1bn of short-term bonds.

  • Trailing twelve months to Jun-2026: operating cash flow KRW -13.64bn, capex KRW 0.20bn, FCF about KRW -13.8bn.

  • Quarterly cash burn in 1Q26 was estimated by independent research at about KRW 2.5–2.8bn (AlphaDistill). That looks optimistic given the 2Q26 loss.

Ratios

Ratios not meaningful or not disclosed

  • ROIC: not meaningful (negative NOPAT).

  • Net debt/EBITDA: not meaningful (net cash and negative EBITDA).

  • Cash conversion cycle: not disclosed and not meaningful at this scale.

  • All ratios are computed from the tables above.

Trend summary. AbClon has never made a profit. Its solvency depends on the equity market's willingness to fund it. The crisis point was FY2023–FY2024:

  • Current ratio near 1.1–1.3.

  • Short-term CB maturities.

  • An administrative-issue designation.

The 2025 raises reset the balance sheet. At about KRW 36bn of cash and short-term instruments (Jun-2026) and an underlying burn of about KRW 14–18bn a year, the company has roughly two years of runway, before:

  • Any AT101 launch costs borne by AbClon.

  • Any repayment if the perpetual CB call/step-up (coupon rising to 4% in year 4) prompts refinancing in 2028–29.

The main non-dilutive inflows in view are:

  • TCT milestones.

  • Henlius sales milestones, which would arrive only after a 2028 launch.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment / revenue line (KRW Bn)

Segment / revenue line (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Total revenue (single segment, KRW Bn)

3.03.42.92.344.71

Operating income (single segment, KRW Bn)

-10.2-8.7-11.6-15.6-17.63

Operating margin (%)

-340-256-400-667-374

Revenue YoY growth (%)

—13.3-14.7-19.3101.3

Revenue type, 2Q26 (% of quarterly revenue)

Revenue type, 2Q26 (% of quarterly revenue)Share

Goods (reagents, standards, antibody detection reagents)

85%

Services

15%

Income Statement and Per-Share Data

Metric (KRW Bn unless stated)FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

3.03.42.92.344.71

Cost of sales (KRW Bn)

————3.57

Gross profit (KRW Bn)

————1.14

SG&A incl. R&D (KRW Bn)

————18.77

R&D expense within SG&A (KRW Bn)

————14.43

Operating income (KRW Bn)

-10.2-8.7-11.6-15.6-17.63

EBITDA (KRW Bn)

————-16.80

Pre-tax income (KRW Bn)

————-17.90

Net income (KRW Bn)

-10.2-9.3-12.9-16.3-17.90

EPS basic (KRW)

————-933

Dividends per share (KRW)

00000

Gross margin (%)

————24.2

Operating margin (%)

-340-256-400-667-374

EBITDA margin (%)

————-357

Net margin (%)

-340-274-445-697-380

Financial Analysis

ItemValue (KRW Bn)

Revenue

5.30

Gross profit

0.67

R&D

14.07

Operating income

-17.85

Net income

-17.42

Total assets

64.50

Cash

30.37

Short-term financial instruments

6.00

Total debt

7.00

Total liabilities

11.43

Equity

53.07

Net cash

29.37

Cash plus short-term instruments

36.3 (NewDaily cites KRW 36.3bn)

Revenue History

QuarterRevenue (KRW Bn)Operating loss (KRW Bn)Net loss (KRW Bn)EPS (KRW)Source

1Q26

0.433.062.78-145

DART via AlphaDistill

2Q26

1.66.26.0—

Valueline, 20 Aug 2026

1H26

2.19.38.8—

NewDaily, Sep-2026

Balance Sheet and Share Count (millions)

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

—54.0245.4348.1870.74

Cash and cash equivalents (KRW Bn)

—5.2912.2518.8639.01

Short-term financial instruments (KRW Bn)

—18.846.573.006.00

Short-term debt incl. current CB (KRW Bn)

—7.0012.5217.107.00

Long-term debt incl. non-current CB (KRW Bn)

—4.56000

Total debt (KRW Bn)

—11.5612.5217.107.00

Net debt (KRW Bn, negative = net cash)

—-12.57-6.30-4.76-38.01

Total liabilities (KRW Bn)

—17.2818.2018.7710.30

Total equity (KRW Bn)

—36.7327.2229.4060.43

Goodwill and intangibles (KRW Bn)

—0.420.530.500.49

Working capital (KRW Bn)

—16.371.725.1236.68

Accumulated deficit (KRW Bn)

—-43.67-56.58-72.88-90.79

Shares outstanding (millions)

15.2815.3215.5317.4319.73

Cash Flow

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

————-13.82

Capex incl. intangibles (KRW Bn)

————0.61

Free cash flow (KRW Bn)

————-14.43

Financing cash flow (KRW Bn)

————37.73

Dividends paid (KRW Bn)

00000

Share buybacks (KRW Bn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE on ending equity (%)

-25.3-47.4-55.4-29.6

ROA on ending assets (%)

-17.2-28.4-33.8-25.3

Current ratio (x)

2.911.101.284.92

Debt to equity (x)

0.310.460.580.12

Asset turnover (x)

0.060.060.050.07

Interest coverage, operating income / interest expense (x)

———-41.0

Revenue by Region

Region (KRW Bn)FY2023FY2024FY2025

Total revenue, all regions (KRW Bn)

2.92.344.71

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (KRW)

—12,80014,82014,12042,500

Year-end market cap (KRW Bn)

—196.07230.16246.04812.27

Year-end shares outstanding (millions)

15.2815.3215.5317.4319.73

Price-to-book at year-end (x)

——8.458.3713.44

Share Price History

DatePrice (KRW)Source

11-Feb

65,100

Dailypharm

—95,800

StockHub; Investing.com

31-Mar

56,700

Valueline

18-May

39,250

AlphaDistill

30-Jun

27,800

Valueline

9-Jul

22,650

AlphaDistill

4-Aug

26,500

AlphaDistill

26-Aug

28,450

Valueline

29-Sep

21,750

Valueline

15-Oct (12:15)

21,350

Valueline

Valuation Multiples

MultipleAbClonNotes

P/E

Not meaningful (losses)

Valueline shows about -26.8x

EV/Sales (trailing twelve months)

About 75x

EV ≈ KRW 426bn market cap minus KRW 29.4bn net cash ≈ KRW 397bn; TTM revenue KRW 5.30bn. Computed.

P/B

About 8.8x

Valueline

Peer: Curocell market cap

About KRW 412bn (Jul-2026)

AlphaDistill

Capital Instruments

InstrumentAmountTerms

Short-term bank borrowings

KRW 7.0bn

Rolled since at least FY2022

Series 2 CB

Converted or partly outstanding; KRW 20bn originally announced, from a KRW 19bn package paid in

Maturity 29-Nov-2029; conversion price KRW 16,244.

Series 3 perpetual CB

KRW 25.2bn

Equity-classified; 30-year maturity (28-Oct-2055); issuer call after 4 years; coupon steps up to 4% in year 4 and +1% a year after, which effectively encourages calling or converting by about Oct-2029

CPS (multiple series)

—

Non-redeemable; equity

Analyst Conclusions

Management guidance (as of Oct-2026)

  • Final nespecel Phase 2 data and an MFDS expedited approval filing by end-2026, targeting launch in 2027 via Chong Kun Dang.

  • HLX22 Phase 3 topline in 1H27 per AbClon, or 2H27 per Henlius' latest guidance; 2028 global launch.

  • AT501 IND in 2026.

  • In vivo CAR-T partnering.

  • Türkiye IND in 2026.

  • No financial guidance.

  • Sources: Dealsite; NewDaily; AbClon IR.

Consensus growth expectations

None available. Independent research estimates FY2026 standalone revenue of about KRW 4.3bn with an operating loss of about KRW 13bn. This is not consensus, and 1H26 actuals (operating loss KRW 9.3bn) suggest the loss estimate is optimistic (AlphaDistill; NewDaily).

Bull case

  1. Nespecel approval in 2027 with a differentiated label. If final Phase 2 data hold a CR rate near the 63–68% interim, nespecel would match Limkato (CR 67.1%) and beat the imported products. Expedited, orphan and GIFT designations, together with CKD's distribution, could support uptake. A post-CAR-T relapse label would be unique.

  2. HLX22 success makes AbClon a royalty company. A positive PHAROS001 readout, building on the Phase 2 PFS hazard ratio of 0.20, would unlock sales milestones (USD 30M gross) and royalties of 3–5% (roughly 65% net to AbClon after Alligator). It would also add value through HLX49 and other derivatives.

  3. Platform licensing. The in vivo CAR-T market has absorbed large acquisitions. An in vivo CD19 programme using a clinically validated binder (Strike, GC) or a licence for AM109 or zCAR-T could bring meaningful non-dilutive cash and re-rate the platform.

Bear case

  1. Second to market in a small, price-controlled country. Curocell's market cap halved after approval as reimbursement and launch timing dragged. Nespecel enters behind it with a smaller partner network and no ex-Korea data, and in vivo CAR-T may shorten the life of the ex vivo category.

  2. HLX22 economics are thin and late. Topline has slipped to 2H27 and launch would come no earlier than 2028. Milestones depend on sales, and zanidatamab may become the HER2 backbone first. A positive trial might still deliver modest cash to AbClon before about 2030.

  3. Dilution is the base case. Burn is about KRW 14–18bn a year against about KRW 36bn of liquidity. Convertibles at KRW 16,244–18,223 are near the money, with a lock-up expiring 28-Oct-2026. The perpetual CB step-up in 2029 adds refinancing pressure, while the stock trades at about 8.8x book and about 75x EV/Sales.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
28-Oct-2026Lock-up expiry on the Series 3 CB and CPS
By 14-Nov-20263Q26 report: cash burn trajectory
4Q26Final nespecel Phase 2 data, any ASH 2026 presentation, and the MFDS approval filing
4Q26–1H27Türkiye IND and TCT milestones; AT501 IND; Asan post-CAR-T investigator-trial IND
2026–2027In vivo CAR-T licence or co-development deal (unconfirmed discussions)
2,026HLX49 IND by Henlius
1H27 vs 2H27Henlius' progress updates on PHAROS001 enrolment (428/550 in Aug-2026) and topline timing
OngoingLimkato reimbursement and uptake as a read-across for nespecel pricing
OngoingAny new equity-linked financing

Analyst verdict

AbClon is a high-quality discovery engine that has struggled to turn science into cash. Its NEST platform has produced two assets that would be a creditable track record for a much larger company.

The first is AC101/HLX22. It is now in a roughly 550-patient global Phase 3, fully funded by Henlius, after a Phase 2 with a PFS hazard ratio of 0.20. The second is nespecel. It is the only late-stage CD19 CAR-T with a proprietary, non-FMC63 binder, and its interim CR rate of 63–68% is competitive with every approved CD19 product.

The financial picture is far weaker:

  • Revenue is a byproduct of reagent tenders (KRW 4.7bn in FY2025).

  • Operating losses have widened to about KRW 18bn.

  • The balance sheet has been repeatedly rebuilt through convertibles priced below today's share price.

  • The economics of the lead antibody were largely given away in 2016–2018. AbClon received USD 11M upfront and is left with sales-based milestones and 3–5% royalties, of which it keeps only about 65%.

The equity story therefore rests on nespecel's commercial and licensing value and on platform optionality, especially in vivo CAR-T. Both face clear headwinds. Curocell's Limkato won the Korean race in April 2026, and its post-approval share price fall shows how cautiously the market values a domestic CAR-T launch.

At about KRW 0.43–0.47tn, the market is pricing substantial success. That is roughly 8.8x book with about two years of cash, and it comes after the stock has fallen sharply from its February 2026 peak.

Our assessment is "high-risk, event-driven — neutral until final nespecel data."

What would change our view:

Positive: final Phase 2 data that hold CR above 60% across the full cohort, together with an ex-Korea licence for nespecel or the in vivo platform.

Negative: further slippage in HLX22 timing, or a financing before the nespecel filing.

Sizing should reflect binary clinical, regulatory and dilution risk over the next 12 months.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleBackgroundSource

Lee Jong-seo (이종서)

Founder, CEO and Representative Director; largest shareholder

Chong Kun Dang R&D researcher 1991–1995. Worked with the Royal Swedish Academy / KTH on the Human Protein Atlas from 2003. Co-founded AbClon with Prof. Mathias Uhlén in 2010.

SmartToday; BioSpectator

Prof. Mathias Uhlén

Co-founder

Leads the Human Protein Atlas (KTH, Sweden).

BioSpectator

Lee Yong-jun (이용준)

Head, CAR-T Center

At Chong Kun Dang 2013–2020

Dealsite (May-2025)

Lee Yoon (이윤)

Head, Clinical Research Institute

Spokesperson for the nespecel regulatory strategy

eToday; BioSpectator (Jul-2025)

Hwang Jin-ha (황진하)

Director, Head of Business Development

Leads partnering at BIO USA 2026

Dealsite (Jul-2026)

Kim Kyu-tae (김규태)

CFO, as of 2019

—

BioSpectator (2019)

Major Shareholders

HolderSharesStakeBasis / dateSource

Lee Jong-seo (CEO)

1,401,675

~7.0–7.3%

Q3-2025 report; 7.66% before the CKD placement, 7.34% after

Dailypharm; Dealsite

Lee Jong-seo plus related parties (including his son)

—

13.06–15.07% (sources differ)

May-2025

Dailypharm; SmartToday

Chong Kun Dang Co., Ltd.

1,400,000

~7.1–7.3%; about 7.0% on the 19.95M share base

Placement at KRW 8,723 per share, paid 19-May-2025.

Dealsite; Dailypharm; AlphaDistill

Daily Partners funds

CB conversion right over 1,231,223 shares (Series 2 CB, KRW 20bn announced) plus CPS

—

Oct-2024 terms; KRW 19bn of the package paid in Dec-2024

BioSpectator; Finance Scope

VC holders of the perpetual CB and CPS (DSC Investment, Paratus Investment, Dongyu Investment, AlphaView Partners, Winvest Venture Investment)

Conversion price KRW 18,223

—

Lock-up expires 28-Oct-2026

Dealsite; AlphaDistill

Foreign ownership

—11.52%

Jun-2021 (historical)

Kyobo Securities

Competitive Landscape

Key Competitors

CompetitorProductStatus / dataPositioning vs nespecel

Novartis

Kymriah (tisagenlecleucel)

Approved; first CAR-T in Korea. Pivotal JULIET: ORR 50%, CR 32%.

Incumbent in Korea. AbClon argues it has a higher CR rate and a different epitope.

Gilead / Kite

Yescarta (axi-cel); Tecartus

Approved globally. ZUMA-1: ORR 72%, CR 51%.

Global leader; FMC63/CD28 construct

Bristol Myers Squibb

Breyanzi (liso-cel)

Approved globally. TRANSCEND: ORR 73%, CR 54%.

Strong safety profile

Autolus

Aucatzyl (obe-cel; modified FMC63)

Approved in the US for adult ALL

Fast-off-rate binder is a conceptually similar argument

Curocell (Korea)

Limkato (anbal-cel)

MFDS approved 29-Apr-2026. Phase 2: ORR 75.3%, CR 67.1%. Reimbursed launch targeted around Sep-2026.

Closest domestic rival and now first to market. Market cap about KRW 412bn (Jul-2026).

AstraZeneca (EsoBiotec), AbbVie (Capstan), Gilead (Interius), BMS (Orbital)

In vivo CAR-T

Clinical or preclinical

Long-term disruptors of ex vivo CAR-T, including AbClon's own

Korean next-generation CAR-T developers (e.g., Verismo)

SynKIR-110 and others

Early clinical

Future domestic competition

Roche

Herceptin (trastuzumab) plus chemotherapy

Standard of care

HLX22 is added to it, not substituted

Merck & Co.

Keytruda plus trastuzumab plus chemotherapy (PD-L1 CPS ≥1)

Approved

Allowed in both arms of PHAROS001

Jazz / Zymeworks / BeOne

Ziihera (zanidatamab), a biparatopic HER2 antibody

HERIZON-GEA-01 positive (n=914). Zanidatamab plus tislelizumab plus chemotherapy reached median OS of 26.4 months. Second interim showed a significant OS gain for zanidatamab plus chemotherapy. sBLA planned for 1H26.

The most direct competitor in dual-epitope HER2 blockade. It may replace trastuzumab as the backbone before HLX22 reads out, which complicates PHAROS001's comparator relevance.

AstraZeneca / Daiichi Sankyo

Enhertu (T-DXd)

Approved later-line in gastric cancer; also a combination partner

Henlius is turning a competitor into a combination partner

Roche

Perjeta (pertuzumab)

Failed to win approval in gastric cancer (JACOB)

Shows dual HER2 blockade is not guaranteed to work

Peer Comparison FY2025

MetricAbClonCurocellHenlius (partner, for scale)Zymeworks (HER2 competitor)

Revenue

KRW 4.7bn (FY2025)

Not compiled

Not compiled (66 approvals globally)

Not compiled

Revenue growth

+101% (FY2025)

Not compiled

Not compiled

Not compiled

Operating margin

-374% (FY2025)

Not compiled

Not compiled

Not compiled

R&D intensity

306% of revenue (FY2025)

Not compiled

Not compiled

Not compiled

Market cap

~KRW 426–467bn (Oct-2026)

~KRW 412bn (Jul-2026)

Not compiled

Not compiled

Lead asset stage

CAR-T: MFDS filing by 2026; HER2 antibody (partnered) in Phase 3

CAR-T approved in Korea (Apr-2026)

Commercial

HER2 bispecific approved (biliary tract); first-line GEA filing

Company Snapshot

$3.3M

Revenue

67

Employees

2010

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Proprietary CD19 binder with broad IP. h1218 is patented in Korea, the US, Japan, China, Canada and Australia, with exclusivity to at least 2038, and avoids FMC63 (AbClon IR, Mar-2026).
  • Competitive interim efficacy. Nespecel's Phase 2 interim showed ORR 94% and CR 68% in 32 evaluable patients, against pivotal benchmarks of Kymriah (50%/32%), Yescarta (72%/51%) and Breyanzi (73%/54%) (AbClon IR; EHA 2025).
  • High manufacturing reliability. 97.8% of enrolled patients' products were manufactured successfully (44 of 45) at the in-house GMP suite (EHA 2025 abstract, BioSpectator).
  • Partner-funded global Phase 3 for AC101. About 550 patients, 77.8% enrolled by Aug-2026, with FDA and EC orphan designations, at no cost to AbClon (NewDaily; BioSpectator).
  • Strong Phase 2 signal for HLX22. PFS hazard ratio 0.20; median PFS not reached at 39 months; two-year PFS 54.8% vs 17.5% (NewDaily; AbClon IR).
  • Strategic domestic partner. Chong Kun Dang owns about 7% and holds Korean sales priority (Dealsite, May-2025).
  • Regulatory fast-tracks. MFDS orphan, expedited-review and GIFT designations for nespecel (Finance Scope, Jul-2026).
  • Repaired balance sheet. Net cash of KRW 29.4bn and a debt-to-equity ratio of 0.13 at Jun-2026 (Valueline).

Weaknesses

  • Tiny, non-core revenue. Revenue was KRW 4.71bn in FY2025, mostly reagent tenders. The company fell below the KRW 3bn KOSDAQ threshold in FY2024 (Dealsite).
  • Persistent losses. Operating losses reached KRW 17.6bn in FY2025, the widest in five years. 1H26 operating loss was KRW 9.3bn (Valueline; NewDaily).
  • Diluted AC101 economics. USD 30M of remaining milestones are all sales-based; royalties are only 3–5%; Alligator takes 35% (NewDaily; Alligator).
  • Small, Korea-only nespecel dataset. Interim results cover 32 patients. Press scrutiny has noted that interim response rates often fall as more patients are added (Dailypharm, Dec-2025).
  • Weak insider control and an overhang of convertibles. Founder and CKD each hold about 7%. Conversion prices of KRW 16,244 and KRW 18,223 sit below the market price (Dealsite; BioSpectator).
  • Thin sell-side coverage. No consensus estimates exist; brokers such as Daol and Shinhan published without targets or estimates (Money Today; AlphaDistill).
  • History of slipping timelines. The nespecel conditional-approval filing was first targeted for 2H24, then 1H25, then 2025, and is now end-2026 (BioSpectator 2023–2025; Dealsite 2026).

Opportunities

  • Korean launch of nespecel in 2027, with CKD distributing, if the end-2026 filing goes ahead (Dealsite, Jul-2026).
  • Patients who relapse after CAR-T. AbClon claims nespecel can work after FMC63-based CAR-T failure; an Asan investigator-initiated trial is planned (Dailypharm; AbClon IR).
  • Ex-Korea licensing. Building on Türkiye, with US pre-IND guidance that Korean Phase 1 data could allow entry at Phase 2 (BioSpectator; MTN, 2023).
  • HLX22 indication expansion. Six indications, plus HLX49, a biparatopic ADC that outperformed Enhertu preclinically, which extends AbClon's derivative economics (Asia Economy; Alligator).
  • In vivo CAR-T demand. Large pharma has paid substantial sums for in vivo platforms, and AbClon has two LNP partners: Strike and GC Biopharma (AbClon IR; BioSpectator).
  • Early-asset licensing. zCAR-T (AT501, IND targeted 2026) and AM109 (complete responses at 0.1–0.3 mg/kg in animals) (BioSpectator; AlphaDistill).

Threats

  • Curocell got there first. Limkato was approved on 29-Apr-2026 with a reimbursed launch targeted around Sep-2026. Curocell's market cap fell by about half after approval, which shows how little the market may reward a domestic CAR-T launch (Dealsite, Apr/Jul-2026).
  • Zanidatamab may become the HER2 backbone. HERIZON-GEA-01 showed an OS gain over trastuzumab, which could weaken the relevance of an HLX22 regimen built on trastuzumab (Jazz/Zymeworks releases).
  • HLX22 topline slipped. Henlius moved it from 1H27 to 2H27, narrowing the path to a 2028 launch (NewDaily, Sep-2026).
  • Phase 3 risk in dual HER2 blockade. Pertuzumab's JACOB failure in gastric cancer is the precedent.
  • Further dilution or refinancing. About two years of runway; a perpetual CB that steps up to a 4% coupon in year 4; a lock-up expiring 28-Oct-2026 (Dealsite; AlphaDistill).
  • Disruption by in vivo CAR-T to ex vivo autologous products, including nespecel (BioSpectator, Jan-2026).
  • High market beta. KOSDAQ fell about 7% on 15-Oct-2026. The stock is down about 54% over six months to late Aug-2026 (NewDaily; Valueline).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar-2025KRX designates AbClon an administrative-issue stock (FY2024 revenue KRW 2.34bn, below KRW 3bn) Dealsite; Korea Economic DailyDelisting-risk overhang
4-Mar-2025TCT licence finalised (signed 28-Feb in Istanbul) BioSpectatorFirst ex-Korea nespecel deal
6-Mar-2025Japan investigators' meeting for HLX22-GC-301 (more than 50 investigators from more than 20 sites) eTodayPhase 3 execution in Japan
Mar-2025FDA Orphan Drug Designation for HLX22 in gastric cancer BioSpectatorUS regulatory incentives
Apr-2025First patient in Phase 2 of HLX22 plus Enhertu for HER2-low HR+ breast cancer (China) AbClon IRIndication expansion
9-May-2025Chong Kun Dang KRW 12.2bn strategic investment DealsiteDomestic commercial partner
16-May-2025EHA abstract: nespecel Phase 2 ORR 94%, CR 63% Finance ScopeData inflection
27-May-2025European Commission Orphan Drug Designation for HLX22 BioSpectatorTen years of EU exclusivity if approved
Jun-2025EHA 2025 poster in Milan; CR updated to 68% BioSpectatorClinical validation
Mid-2025First US patient dosed in HLX22 Phase 3 BioSpectatorGlobal trial footprint
24-Jul-2025Expedited-review application to MFDS eTodayRegulatory acceleration
27-Aug-2025KDCA reagent contract (KRW 309M) DigitalTodaySupports the revenue threshold
Sep-2025US zCAR-T platform patent KormediIP for solid-tumour CAR-T
24-Sep-2025MFDS expedited-review designation for nespecel Korea Economic DailyPriority review, possible data waivers
1-Oct-2025KRW 36bn perpetual CB and CPS DealsiteCures the pre-tax-loss test
21-Oct-2025Australian nespecel patent DailypharmIP breadth
Late 2025MFDS development-stage orphan designation for nespecel Dailypharm headlineExpedited approval eligibility
1-Dec-2025Press scrutiny of nespecel's competitiveness: interim data based on 32 evaluable patients DailypharmHighlights the risk that final data come in lower
10-Dec-2025CEO says 2026 will be a leap year; cites KRW 48.4bn raised in 2025 Korea Economic DailySentiment
8-Jan-2026Zanidatamab HERIZON-GEA-01 first-line HER2+ GEA Phase 3 data at ASCO GI (competitor) MarketScreener; AJMCRaises the bar for HLX22
29/30-Jan-2026In vivo CAR-T platform announced; FY2025 revenue of KRW 4.7bn disclosed BioSpectator; KukinewsNew narrative; listing risk resolved
10/11-Feb-2026Strike Pharma Eurostars grant; share price above KRW 65,000 CB Insights; DailypharmValuation peak period
Feb-2026First patient for HLX22 plus HLX87 in breast cancer; HER2-low breast Phase 2 fully enrolled AbClon IRHenlius extends the franchise
9-Mar-2026NIFDS reagent contract (KRW 778M) DealsiteRevenue support
Mar-2026Administrative-issue designation lifted; investor presentation (12-Mar) AlphaDistill; KRX KINDListing normalised
17–22 Apr-2026AACR 2026: AM109 and zCAR-T data; Henlius presents HLX49 BioSpectator; Asia EconomyPartnering catalysts
29-Apr-2026Curocell's Limkato approved as Korea's first domestic CAR-T (competitor) DealsiteRemoves AbClon's first-to-market chance in Korea
15-May-20261Q26 results: revenue KRW 0.43bn; operating loss KRW 3.06bn AlphaDistillRevenue miss; cost cut
20-May-2026Chong Kun Dang lock-up expires AlphaDistillOverhang
2-Jun-2026Daol Investment report (no rating or target) Money TodayIncreasing sell-side attention
17-Jun-2026GC Biopharma in vivo CAR-T partnership BioSpectatorPlatform validation
23-Jun-2026BIO USA: BD head confirms filing by year-end and launch in 2027 DealsiteTimeline reaffirmed
2-Jul-2026Nespecel Phase 2 enrolment completed Finance ScopeKey milestone
Jul-2026HLX22 Phase 3 first patients dosed on all continents; CD30 CAR-T US patent; CPS overhang resolved AlphaDistill; Asia EconomyExecution
4-Aug-2026NIFDS contract (KRW 824M); Shinhan Investment initiates; stock up 20.73%; one-day investment-caution designation AlphaDistillSentiment spike
13-Aug-2026Shareholder letter guides HLX22 topline to 1H27; half-year report filed NewDailyGuidance
20-Aug-20262Q26: revenue KRW 1.6bn (+51% YoY); operating loss KRW 6.2bn ValuelineBurn back up
2-Sep-2026Henlius moves HLX22 topline to 2H27; 428 of 550 patients enrolled NewDailyTiming risk
29-Sep-2026Stock rises 12.6% to KRW 21,750 ValuelineVolatility
15-Oct-2026KOSDAQ falls about 7% (US CPI and AI-profitability shock); AbClon down 8.8% intraday to KRW 21,350 NewDaily; ValuelineMarket beta

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 3,000 Mn in FY2021 to KRW 4,710 Mn in FY2025.
AbClon Inc. — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue3,0003,4002,9002,3404,710
Cost of sales————3,570
Gross profit————1,140

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. AbClon Investor Relations deck, Mar-2026 (KRX KIND) (kind.krx.co.kr)
  2. Valueline (DART-derived statements, prices)
  3. Balance sheet (valueline.co.kr)
  4. Income statement (valueline.co.kr)
  5. Cash flow (valueline.co.kr)
  6. Summary (valueline.co.kr)
  7. Butler.works company page (butler.works)
  8. NewDaily (2 Sep 2026), HLX22 timing, deal terms, 1H26 (biz.newdaily.co.kr)
  9. Alligator Bioscience on HLX49 (Apr-2026) (1stoncology.com)
  10. BioSpectator articles (AT101, HLX22, TCT, CB/CPS, in vivo CAR-T, AACR 2026, GC Biopharma)
  11. biospectator.com
  12. biospectator.com
  13. biospectator.com
  14. biospectator.com
  15. biospectator.com
  16. biospectator.com
  17. biospectator.com
  18. biospectator.com
  19. biospectator.com
  20. biospectator.com
  21. biospectator.com
  22. biospectator.com
  23. biospectator.com
  24. Dealsite articles
  25. dealsite.co.kr
  26. dealsite.co.kr
  27. dealsite.co.kr
  28. dealsite.co.kr
  29. dealsite.co.kr
  30. dealsite.co.kr
  31. dealsite.co.kr
  32. dealsite.co.kr
  33. dealsite.co.kr
  34. dealsite.co.kr
  35. Dailypharm
  36. dailypharm.com
  37. dailypharm.com
  38. dailypharm.com
  39. Korea Economic Daily (Hankyung)
  40. hankyung.com
  41. hankyung.com
  42. hankyung.com
  43. Finance Scope
  44. finance-scope.com
  45. finance-scope.com
  46. finance-scope.com
  47. Kukinews (FY2025 revenue, 30 Jan 2026) (kukinews.com)
  48. AlphaDistill independent research
  49. alphadistill.com
  50. alphadistill.com
  51. alphadistill.com
  52. Money Today (Daol report, Jun-2026) (mt.co.kr)
  53. Money Today (Curocell press conference, May-2026) (mt.co.kr)
  54. DigitalToday (KDCA contract) (digitaltoday.co.kr)
  55. Asia Economy (HLX49, AACR 2026) (view.asiae.co.kr)
  56. THE VC company profile (thevc.kr)
  57. Investing.com quote page (kr.investing.com)
  58. StockHub (stockhub.kr)
  59. CB Insights (Strike Pharma Eurostars item) (cbinsights.com)
  60. Kormedi (zCAR-T US patent, competitive context) (kormedi.com)
  61. Zymeworks HERIZON-GEA-01 release (ir.zymeworks.com)
  62. MarketScreener (HERIZON-GEA-01 ASCO GI 2026) (marketscreener.com)
  63. KTB Securities company note (2019) (file.alphasquare.co.kr)
  64. Kyobo Securities company report (Jun-2021) (file.alphasquare.co.kr)
  65. PR Newswire / BioSpace (AACR 2023) (biospace.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.